Loss of MAP3K1 expression activates the PI3K/AKT/mTOR pathway and desensitizes the tumor to PI3K inhibition (Avivar‐Valderas et al, 2018), thus mutation status of this gene may affect efficacy of PI3K‐targeting drugs. Here, MAP3K1 is linked to neoplasm.